213 related articles for article (PubMed ID: 31851783)
1. Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages.
Li G; Zhai Y; Wang Z; Wang Z; Huang R; Jiang H; Li R; Feng Y; Chang Y; Jiang T; Zhang W
Cancer Med; 2020 Mar; 9(6):1955-1965. PubMed ID: 31851783
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for glioblastoma therapy associated complications.
Ening G; Osterheld F; Capper D; Schmieder K; Brenke C
Clin Neurol Neurosurg; 2015 Jul; 134():55-9. PubMed ID: 25942630
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Data Base.
Amsbaugh MJ; Yusuf MB; Gaskins J; Burton EC; Woo SY
Cancer; 2017 Sep; 123(17):3277-3284. PubMed ID: 28452053
[TBL] [Abstract][Full Text] [Related]
4. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.
Kostopoulou ON; Mohammad AA; Bartek J; Winter J; Jung M; Stragliotto G; Söderberg-Nauclér C; Landázuri N
Int J Cancer; 2018 Mar; 142(6):1266-1276. PubMed ID: 29067692
[TBL] [Abstract][Full Text] [Related]
6. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.
Niyazi M; Pitea A; Mittelbronn M; Steinbach J; Sticht C; Zehentmayr F; Piehlmaier D; Zitzelsberger H; Ganswindt U; Rödel C; Lauber K; Belka C; Unger K
Oncotarget; 2016 Jul; 7(29):45764-45775. PubMed ID: 27302927
[TBL] [Abstract][Full Text] [Related]
7. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Oh SW; Jee TK; Kong DS; Nam DH; Lee JI; Seol HJ
Acta Neurochir (Wien); 2014 Apr; 156(4):641-51. PubMed ID: 24553726
[TBL] [Abstract][Full Text] [Related]
8. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
9. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
10. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
11. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme.
Brzozowska A; Toruń A; Mazurkiewicz M
Adv Clin Exp Med; 2015; 24(2):279-87. PubMed ID: 25931361
[TBL] [Abstract][Full Text] [Related]
12. Current clinical management of patients with glioblastoma.
Lowe S; Bhat KP; Olar A
Cancer Rep (Hoboken); 2019 Dec; 2(6):e1216. PubMed ID: 32721125
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Bouchart C; Trépant AL; Hein M; Van Gestel D; Demetter P
Cancer Med; 2020 Feb; 9(3):1069-1078. PubMed ID: 31568682
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
Lehrer S; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
16. Management of glioblastoma: State of the art and future directions.
Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M
CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924
[TBL] [Abstract][Full Text] [Related]
17. Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Kiang KM; Chan AA; Leung GK
BMC Cancer; 2021 Mar; 21(1):265. PubMed ID: 33706745
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
19. A novel methylation signature predicts radiotherapy sensitivity in glioma.
Feng Y; Li G; Shi Z; Yan X; Wang Z; Jiang H; Chen Y; Li R; Zhai Y; Chang Y; Zhang W; Yuan F
Sci Rep; 2020 Nov; 10(1):20406. PubMed ID: 33230136
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
Indraccolo S; De Salvo GL; Verza M; Caccese M; Esposito G; Piga I; Del Bianco P; Pizzi M; Gardiman MP; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Zagonel V; Lombardi G
Clin Cancer Res; 2020 Sep; 26(17):4478-4484. PubMed ID: 32518098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]